Bafna Pharmaceuticals Ltd (BAFNAPH)
·Next Day Close·+1.99%·₹363.05
Key EventTrading window closure announced for quarter-end results
Bafna Pharmaceuticals Ltd (BAFNAPH)
·Next Day Close·+1.96%·₹308.95
Key Event31st AGM resolutions passed with requisite majority
ImpactShareholders approved key governance and financial items, reinforcing board continuity and auditor remuneration without dissent.Sign up to read impact
Bafna Pharmaceuticals Ltd (BAFNAPH)
·Next Day Close·+1.96%·₹308.95
Key Event31st AGM approved FY2026 financials and reappointed director
ImpactShareholders approved key governance and financial items with no new capital plans disclosed.Sign up to read impact
Bafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·-1.98%·₹242.2
Key Event31st AGM scheduled for September 11, 2026 via Video Conferencing
ImpactStrong profitability growth and regulatory progress position Bafna for expanded global market access and sustainable value creationSign up to read impact
Bafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·-2%·₹262.4
Key Event31st AGM scheduled for September 11, 2026 via video conference
Bafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·-2%·₹262.4
Key Event31st AGM scheduled for September 11, 2026 via video conference
ImpactShareholders can vote remotely before the meeting, but must meet the September 4 eligibility deadline.Sign up to read impact
Bafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·-1.99%·₹273.2
Key EventBoard approved Q1 FY27 results and set AGM date
Bafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·+1.99%·₹207.55
Bafna Pharmaceuticals Limited received a SEBI-mandated certificate from Cameo Corporate Services Limited confirming dematerialized securities for the quarter ended June 30, 2026, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate verifies that securities were accepted by depositories and registered with exchanges.
Sign up to read summaryBafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·+4.94%·₹208.3
Bafna Pharmaceuticals announced that its designated insiders and immediate relatives must remain in a trading window closure from July 1 to August 2, 2026, following SEBI regulations, ahead of the un-audited Q1 FY2026 results release.
Sign up to read summaryBafna Pharmaceuticals Limited (BAFNAPH)
·Next Day Close·+4.99%·₹180.05
Bafna Pharmaceuticals announced the retirement of Independent Director Navin Kumar effective June 22, 2026, triggering board committee reshuffles. Mr. Palamadai Krishnan Sundaresan assumes chairmanship of both Audit and Nomination & Remuneration Committees, while Mrs. Ravichandran Chitra and Mrs. Akila Chintalapati Raju join as members. The transition maintains regulatory compliance and preserves board structure without altering operational outlook.
Sign up to read summary